Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-immune checkpoint monoclonal antibodies - HiFiBiO Therapeutics

X
Drug Profile

Research programme: anti-immune checkpoint monoclonal antibodies - HiFiBiO Therapeutics

Alternative Names: HFB-2005; HFB-2006; HFB-2012; HFB2005 series - HiFiBiO Therapeutics; HFB2006 series - HiFiBiO Therapeutics; HFB2012 series - HiFiBiO Therapeutics

Latest Information Update: 12 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HiFiBiO
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; B cell inhibitors; Phagocyte stimulants; T lymphocyte inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders; Cancer

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 09 Mar 2021 Research programme: anti-immune checkpoint monoclonal antibodies - HiFiBiO Therapeutics is available for licensing as of 09 Mar 2021. https://hifibio.com/partnership/
  • 20 Aug 2020 Preclinical trials in Autoimmune disorders in USA (Parenteral) before August 2020 (HiFiBio Therapeutics' pipeline, August 2020)
  • 20 Aug 2020 Preclinical trials in Cancer in USA (Parenteral) before August 2020 (HiFiBio Therapeutics' pipeline, August 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top